Get the Stockscreener App
0.00
100.00%
-8.28
After Hours:
8.45
8.45
+
Cybin Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Cybin Inc., a biotechnology company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Cybin U.S., and Natures Journey. The Serenity Life and Cybin U.S. segment engages in the research and development of psychedelic pharmaceutical products. The Natures Journey segment focuses on non-psychedelic medicinal mushroom nutraceutical products. It develops CYB001, a drug candidate that is in phase IIa/b for major depressive disorder; CYB003, a deuterated tryptamine preclinical program to treat alcohol use disorder; CYB004, a deuterated tryptamine preclinical program for therapy resistant psychiatric disorder; and CYB005, a phenethylamine preclinical program for psychiatry and neurology. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada.
See More
Previous Close:
$8.28
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$413.12M
Revenue:
-
Net Income/Loss:
$-52.07M
P/E Ratio:
0.00
EPS:
-0.2077
Net Cash Flow:
$-44.93M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$9.83
Cybin Inc Stock (CYBN) Company Profile
Name
Cybin Inc
Sector
Industry
Phone
908 764 8385
Address
100 King Street West, Suite 5600, Toronto
Compare CYBN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYBN
Cybin Inc
|
0.00 | 413.12M | 0 | -52.07M | -44.93M | -0.2077 |
VRTX
Vertex Pharmaceuticals Inc
|
436.95 | 114.32B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
698.25 | 74.74B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
799.32 | 51.13B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.98 | 39.18B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
145.66 | 31.78B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cybin Inc Stock (CYBN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-26 | Initiated | TD Cowen | Buy |
| Feb-02-26 | Initiated | Jefferies | Buy |
| Mar-13-25 | Initiated | Guggenheim | Buy |
| Nov-19-21 | Downgrade | Maxim Group | Buy → Hold |
Cybin Inc Stock (CYBN) Latest News
Helus Pharma reports encouraging Phase 2 results for HLP004 anxiety treatment - MSN
Top Cybin (HELP) Competitors 2026 - MarketBeat
Point72 / Cohen disclose 686,669 shares in Cybin (CYBN) - Stock Titan
Sirenia (CYBN) discloses 3,677,966 shares; 7.2% stake including warrants - Stock Titan
Cybin stands out as the most undervalued psychedelic stock as Trump signs on faster PTSD research - MSN
Cybin (HELP) Institutional Ownership 2026 $HELP - MarketBeat
Number of shareholders of Cybin Inc. – NASDAQ:HELP - TradingView
BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director - The Globe and Mail
Helus Pharma propels therapeutic innovation in mental health and commences trading on Nasdaq - MSN
TradingKey - TradingKey
EDGAR Filing Documents for 0001628280-25-033606 - SEC.gov
symbol__ Stock Quote Price and Forecast - CNN
Cybin Inc. (NASDAQ:HELP) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
HELP Technical Analysis & Stock Price Forecast - Intellectia AI
Cybin (NASDAQ:HELP) Shares Up 2.7%Should You Buy? - MarketBeat
Helus Pharma Partners With TARA Mind to Boost Phase 3 Depression Trial in Veterans After U.S. Executive Order - TipRanks
Helus Pharma (Nasdaq: HELP) partners with TARA Mind to boost veteran trial access - Stock Titan
CORRECTION: Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health - Investing News Network
Cybin Inc. will Change its Name to Helus Pharma - marketscreener.com
Helus Pharma CEO to Spotlight Mental Health Innovation at 29th Milken Global Conference - TipRanks
Helus Pharma (CYBN) interim CEO to join Milken Global Conference health innovation panel - Stock Titan
Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference - The Manila Times
A Milken health-innovation panel will feature Helus Pharma's interim CEO - Stock Titan
Helus turns to TARA Mind to reach veterans for depression trial - Stock Titan
MSN Money - MSN
Helus Pharma Partners With TARA Mind to Boost Phase 3 Trial Recruitment for Major Depressive Disorder in Veterans - MEXC
Helus Pharma Aligns With U.S. Veteran Mental Health Push in New TARA Mind Partnership - TipRanks
Cybin (CYBN) Helus Pharma joins TARA Mind to boost HLP003 Phase 3 veteran trial - Stock Titan
Cybin to move US stock listing to Nasdaq from NYSE American - MSN
Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health - Investing News Network
Helus Pharma partners with TARA Mind for trial recruitment - Investing.com
Helus Pharma partners with TARA Mind for trial recruitment By Investing.com - Investing.com UK
HELP | Cybin Inc. Common Stock Insider Trading - Quiver Quantitative
Cybin initiates at-the-market equity program of up to $100 million - MSN
Biggest stock movers Wednesday: Vanda Pharmaceuticals, Axsome Therapeutics and Cybin - MSN
Helus Pharma CEO Michael Cola steps down; Eric So takes interim CEO role - MSN
Does Robert Langer’s Arrival Reframe Confidence in Cybin’s (HELP) Clinical Strategy and Execution Risk? - Yahoo Finance
Cybin Inc Stock (CYBN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.71%
Cap:
|
Volume (24h):